Non-interventional Cohort Study of Patients Treated With Lisocabtagene Maraleucel (Liso-cel) for Relapsed/Refractory Mantle Cell Lymphoma in the Post-Marketing Setting
Latest Information Update: 29 Jan 2025
Price :
$35 *
At a glance
- Drugs Lisocabtagene-maraleucel (Primary)
- Indications Mantle-cell lymphoma
- Focus Adverse reactions
- Sponsors Juno Therapeutics
- 29 Jan 2025 New trial record